Evidence map›Paper›PMID 31015763›Full record

ArticleOncoTargets and therapy2019

Molecular subtype classification of papillary renal cell cancer using miRNA expression.

Changwen Yu, Danjing Dai, Juan Xie

Abstract read
In one paragraph

Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Novel variants inExperimental and therapeutic medicine · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Changwen YuDepartment of Oncology, The People's Hospital of Hanchuan City, Hanchuan 431600, Hubei, People's Republic of China, juanxies@163.com.
Danjing DaiDepartment of Oncology, The People's Hospital of Hanchuan City, Hanchuan 431600, Hubei, People's Republic of China, juanxies@163.com.
Juan XieDepartment of Oncology, The People's Hospital of Hanchuan City, Hanchuan 431600, Hubei, People's Republic of China, juanxies@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenal papillary cell carcinoma (KIRP) is a relatively rare renal malignancy. Although KIRP subtyping about clinical relevance has been defined, there have been scarce number of studies on the molecular characteristics of KIRP subtypes.

methodIn this study, a independent samples

resultsFrom solutions with 2, 3, 4, 5, 6 and 7 clusters we selected three KIRP molecular subtypes after assessing PCA, PAC, CDF and consensus heatmaps. We found that the three subtypes are associated with different overall survival and molecular characteristics. Compared with subtype1 and subtype3, subtype2 had a better prognosis in KIRP patients. After exploring their signaling pathways and biological characteristics, we identified the significantly enriched KEGG pathways and Gene Ontology terms for the three subtypes. The distribution of PARD6B, SETD2, STAG2, CUL3, TNRC18, LRBA, IGSF9B and DUNC1H1 mutations differed between the subtypes.

conclusionWe performed unsupervised clustering using differentially expressed miRNA expression data and described the three KIRP molecular subtypes. The three subtypes differed in overall survival, molecular characteristics and gene mutation frequency.

Indexed as

molecular subtypeprognosisrenal papillary cell carcinomaunsupervised clustering

Identifiers

PMID31015763
PMCPMC6446988

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.